SEATTLE--(BUSINESS WIRE)--May 22, 2018--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on
discovering and developing innovative, protein-based immunotherapies
targeting the immune synapse to treat cancer, autoimmune/inflammatory,
and other diseases, today announced the company will present at the
Jefferies 2018 Global Healthcare Conference on Tuesday, June 5 2018 at
4:30 pm Eastern Time in New York, NY.
A live webcast of the presentation will be available online in the
investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events.
A replay of the presentation will be available on the company website
for 90 days following the webcast.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is focused on developing novel
protein-based immunotherapies based upon its variant Ig Domain (vIgD)
technology. vIgDs are engineered to interact with multiple immune
targets, including many present in the immune synapse. Alpine’s vIgDs
are developed with its proprietary platform technology utilizing a
process known as directed evolution, which produces proteins capable of
either enhancing or diminishing an immune response and making vIgD-based
therapeutics potentially capable of treating cancer,
autoimmune/inflammatory, and other diseases. Alpine has also developed
Transmembrane Immunomodulatory Protein (TIP) technology, based on vIgD
technology, to potentially enhance engineered cellular therapies. For
more information, visit www.alpineimmunesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180522005473/en/
Source: Alpine Immune Sciences, Inc.
For Alpine Immune Sciences, Inc.
Courtney Dugan, 212-257-6723